CA3088177A1 - Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis - Google Patents

Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis Download PDF

Info

Publication number
CA3088177A1
CA3088177A1 CA3088177A CA3088177A CA3088177A1 CA 3088177 A1 CA3088177 A1 CA 3088177A1 CA 3088177 A CA3088177 A CA 3088177A CA 3088177 A CA3088177 A CA 3088177A CA 3088177 A1 CA3088177 A1 CA 3088177A1
Authority
CA
Canada
Prior art keywords
drug
ibutamoren
antagonist
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3088177A
Other languages
English (en)
French (fr)
Inventor
Michael Oliver Thorner
Roy G. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lumos Pharma Inc
Original Assignee
Lumos Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lumos Pharma Inc filed Critical Lumos Pharma Inc
Publication of CA3088177A1 publication Critical patent/CA3088177A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3088177A 2018-02-14 2019-02-14 Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis Pending CA3088177A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630361P 2018-02-14 2018-02-14
US62/630,361 2018-02-14
PCT/US2019/017964 WO2019161025A1 (en) 2018-02-14 2019-02-14 Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
CA3088177A1 true CA3088177A1 (en) 2019-08-22

Family

ID=67620042

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3088177A Pending CA3088177A1 (en) 2018-02-14 2019-02-14 Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Country Status (10)

Country Link
US (3) US20210059993A1 (https=)
EP (3) EP4623929A3 (https=)
JP (3) JP2021513552A (https=)
KR (2) KR20200121308A (https=)
CN (2) CN118453597A (https=)
AU (2) AU2019222736B2 (https=)
BR (1) BR112020016613A2 (https=)
CA (1) CA3088177A1 (https=)
EA (1) EA202091464A1 (https=)
WO (1) WO2019161025A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3947426A4 (en) * 2019-03-29 2023-01-04 The General Hospital Corporation GHRH OR ANALOGUES FOR USE IN THE TREATMENT OF HEPATIC DISEASE

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022059946A1 (ko) * 2020-09-18 2022-03-24 서울대학교 산학협력단 비알코올성 지방간염 및 간 섬유화의 치료를 위한 약학적 조성물
KR20220132312A (ko) 2021-03-23 2022-09-30 한국과학기술원 간세포의 IFN-γR1 매개 지질생성작용 억제를 통한 비알코올성 지방간 질환의 치료 방법
KR20250107210A (ko) * 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형
WO2025193784A1 (en) * 2024-03-12 2025-09-18 Lumos Pharma, Inc. Pharmaceutical formulations for maintaining lean muscle mass during weight loss treatment
WO2025217521A1 (en) * 2024-04-12 2025-10-16 Jnana Therapeutics Inc. Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist
CN119405782A (zh) * 2025-01-06 2025-02-11 山东大学 胰岛素样生长因子结合蛋白-1在制备治疗非酒精性脂肪性肝病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US20070123470A1 (en) * 2003-10-24 2007-05-31 Wladimir Hogenhuis Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue
JP2007532495A (ja) * 2004-04-07 2007-11-15 ガストロテック・ファルマ・アクティーゼルスカブ グレリン欠乏を治療するための分泌促進薬の使用
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
BR112017004708A2 (pt) * 2014-09-12 2017-12-05 Tobira Therapeutics Inc terapia de combinação de cenicriviroc para o tratamento de fibrose
US20180360846A1 (en) * 2015-09-16 2018-12-20 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
WO2019008554A1 (en) * 2017-07-06 2019-01-10 Conte Anthony METHOD FOR ORAL TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3947426A4 (en) * 2019-03-29 2023-01-04 The General Hospital Corporation GHRH OR ANALOGUES FOR USE IN THE TREATMENT OF HEPATIC DISEASE
US11738066B2 (en) 2019-03-29 2023-08-29 The General Hospital Corporation GHRH or analogues thereof for use in treatment of hepatic disease
US12233107B2 (en) 2019-03-29 2025-02-25 The General Hospital Corporation GHRH or analogues thereof for use in treatment of hepatic disease

Also Published As

Publication number Publication date
JP2025179056A (ja) 2025-12-09
US20250281470A1 (en) 2025-09-11
EP4623929A2 (en) 2025-10-01
BR112020016613A2 (pt) 2020-12-22
EP4623929A3 (en) 2025-12-17
EP3781158A1 (en) 2021-02-24
EP4467158A2 (en) 2024-11-27
AU2019222736B2 (en) 2024-08-01
WO2019161025A1 (en) 2019-08-22
JP2021513552A (ja) 2021-05-27
AU2019222736A1 (en) 2020-07-30
EA202091464A1 (ru) 2020-12-07
CN118453597A (zh) 2024-08-09
KR20200121308A (ko) 2020-10-23
US20210059993A1 (en) 2021-03-04
EP3781158A4 (en) 2022-03-16
CN111727041A (zh) 2020-09-29
KR20240015742A (ko) 2024-02-05
EP4467158A3 (en) 2025-02-19
US20230381158A1 (en) 2023-11-30
AU2024205599A1 (en) 2024-08-22
JP2024028337A (ja) 2024-03-04

Similar Documents

Publication Publication Date Title
CA3088177A1 (en) Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
TWI621624B (zh) 合成的三萜系化合物及其使用於治療疾病之方法
CN105873576B (zh) 治疗肥胖
US20080249168A1 (en) Pharmaceutical composition for gout
JP2023531164A (ja) 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト
TW200918049A (en) Compounds useful as medicaments
US20250241992A1 (en) Compositions and methods for treating metabolic diseases
JP2001513082A (ja) ヒト成長ホルモンとコルチゾール合成阻害剤とを組み合わせて含む代謝症候群の処置用製剤
US20210283105A1 (en) Novel regimes of fxr agonists
EP4534095A2 (en) Treatment method using mazdutide
US20210121418A1 (en) Treatment of proteinuria
CN101631558A (zh) 基于艾塞那肽和达拉根的用于治疗糖尿病的药物、其用途和治疗模式
JP7569492B2 (ja) 抗精神病薬誘発性体重増加のミリコリラントによる治療方法
HK40034973A (en) Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
WO2026032421A1 (en) Anti-overdosing compositions and uses thereof
US20260069586A1 (en) Methods for reducing weight and preserving or increasing tissue lean mass in patients suffering from cushing's syndrome
US20250367218A1 (en) Methods of treating metabolic disorders and combination products for use in the same
WO2025124473A1 (zh) Glp-1类似物治疗代谢疾病的方法及医药用途
WO2026052859A1 (en) Treatment with dapiglutide
HK40118093A (en) Treatment method using mazdutide
WO2026035940A1 (en) Treatment of obesity
US20260034076A1 (en) Compositions and methods for treating pancreatic disease including type 3c diabetes
WO2026063508A1 (ja) 医薬組成物
WO2026090181A1 (en) Glp-1 receptor agonist combinations and use thereof for increasing weight loss while improving muscle mass and strength

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250203

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250203

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250304

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED

Effective date: 20250703

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250904

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251119

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260203